Clinical Trial Update: GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for GL-ONC1 oncolytic immunotherapy in recurrent or refractory ovarian cancer (Phase 1/Phase 2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinomatosis

Drugs mentioned

• GL-ONC1

Snippet

Sponsor: Genelux Corporation | Conditions: Ovarian Cancer, Peritoneal Carcinomatosis | Phase 1, Phase 2 | Status: COMPLETED